Table 1.
Syphilis serology test of serum and CSF in HIV-positive and HIV-negative patients
| Age/gender/race | HIV | Serology | CSF Pa; Cb | CD4c | HIV-1 viral loadd | Last RPR | |
|---|---|---|---|---|---|---|---|
| 1 | 40/M/B | + | RPR+ (1:64); FTA-ABS+ | NR P:30; W:21 |
535 | 24,561 | NR (5 years) |
| 2 | 43/M/H | + | RPR+ (1:1024); FTA-ABS+ | FTA-ABS+ P:46; W:4 |
137 | >5,000,000 | 1:64 (15 months) |
| 3 | 20/M/H | + | RPR+ (1:2048); FTA-ABS+ | FTA-ABS+ P:97; W:189 |
376 | 189,089 | 1:16 (10 months) |
| 4 | 28/M/W | + | RPR+ (1:16,384); FTA-ABS+ | VDRL+ P:36; W:7 |
127 | 496,559 | 1:16 (1 year) |
| 5 | 27/M/H | + | RPR+ (1:512); FTA-ABS+ | VDRL+ P:79; W:18 |
134 | NA | NA |
| 6 | 48/M/W | + | RPR+ (1:64); FTA-ABS+ | FTA-ABS+ P:43; W:37 |
124 | 224,685 | NA |
| 7 | 49/M/H | + | RPR+ (1:64); FTA-ABS+ | NR P:25; W:3 |
NA | NA | 1:8 (4 months) |
| 8 | 25/M/B | + | RPR+ (1:1024); FTA-ABS+ | NR P:20; W:0 |
134 | NA | NA |
| 9 | 46/M/H | + | RPR+ (1:1024); FTA-ABS+ | FTA-ABS+ P:23; W:1 |
371 | 117,779 | 1:64 (1 month) |
| 10 | 50/M/H | + | RPR+ (1:256); FTA-ABS+ | NA NA |
201 | NA | NA |
| 11 | 59/M/H | − | RPR+ (1:2); FTA-ABS+ | NR P:543; W:2 |
1:2 (1 month) | ||
| 12 | 63/M/H | − | RPR+ (1:2); FTA-ABS+ | NR P:63; W:1 |
NA | ||
| 13 | 51/M/B | − | RPR+ (1:2); FTA-ABS+ | NR P:48; W:0 |
NA | ||
| 14 | 52/M/H | − | RPR+ (1:2); FTA-ABS+ | NR P:50; W:3 |
NR | ||
| 15 | 58/M/B | − | RPR+ (1:8); FTA-ABS+ | NR P:20; W:1 |
1:8 (6 months) | ||
| 16 | 55/M/O | − | RPR+ (1:2048); FTA-ABS+ | VDRL+ P:86; W:6 |
1:128 (1 year) |
B black, W white, H Hispanic, M male, RPR rapid plasma reagin, FTA-ABS fluorescent treponemal antibody absorption, NR non-reactive, NA not available
aCSF protein mg/dl
bCSF WBC count cell/ml
ccell/ml
dcopies/ml